Memantine Oral Tablet

DRUG5 trials

Sponsors

University of Roma La Sapienza, First Affiliated Hospital Xi'an Jiaotong University, Tata Memorial Centre, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, Carnot Laboratories

Conditions

Alzheimer DiseaseCognitive ImpairmentDrug EffectEfficacyNeurocognitive DysfunctionObsessive-Compulsive DisorderRadiation DiseaseSafety

Phase 2

Early Application of Memantine and Pioglitazone to Protect Cognitive Function After Radiotherapy

Not yet recruitingNCT06594172

Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityCognitive Impairment, Drug Effect, Radiation Disease

Start: 2024-09-10End: 2027-06-30Target: 67Updated: 2024-09-19

Phase 3

Memantine for Refractory OCD Patients

University of Roma La SapienzaObsessive-Compulsive Disorder

Start: 2021-09-01End: 2022-12-31Target: 20Updated: 2021-08-20

Evaluation of Memantine in the Preservation of Memory and Neurocognition Following CSI

RecruitingNCT06275035

Tata Memorial CentreNeurocognitive Dysfunction

Start: 2024-02-22End: 2031-01-31Target: 101Updated: 2025-04-09

Phase 4

Efficacy and Safety of Memantine and Sodium Oligomannate in Patients With Moderate to Severe Alzheimer's Disease

First Affiliated Hospital Xi'an Jiaotong UniversityAlzheimer Disease, Efficacy, Safety +1

Start: 2022-07-01End: 2024-12-31Target: 150Updated: 2022-07-07

Satisfaction With Orodispersible vs Conventional Memantine in Moderate to Severe Alzheimer's Disease

CompletedNCT07417670

Carnot LaboratoriesAlzheimer Disease

Start: 2024-10-04End: 2025-08-18Updated: 2026-02-18

Related Papers

Memantine for Refractory Obsessive-Compulsive Disorder: Protocol for a Pragmatic, Double-blind, Randomized, Parallel-Group, Placebo-Controlled, Monocenter Trial

JMIR Research Protocols2023-03-211 citations